Frederick R Appelbaum
Overview
Explore the profile of Frederick R Appelbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
334
Citations
19350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Othus M, Garcia-Manero G, Appelbaum F, Erba H, Dietrich E, Raychaudhuri S, et al.
Leukemia
. 2025 Jan;
39(3):752-754.
PMID: 39870766
No abstract available.
2.
Orvain C, Milano F, Rodriguez-Arboli E, Othus M, Petersdorf E, Sandmaier B, et al.
Leukemia
. 2024 Dec;
39(2):381-390.
PMID: 39668236
Lack of HLA-matched related/unrelated donor remains a barrier to allogeneic hematopoietic cell transplantation (HCT) for adult acute myeloid leukemia (AML), with ongoing uncertainty about optimal donor type if more than...
3.
4.
Ali N, Othus M, Rodriguez-Arboli E, Orvain C, Milano F, Sandmaier B, et al.
Blood Adv
. 2024 Oct;
9(3):558-570.
PMID: 39374582
Measurable residual disease (MRD) by multiparametric flow cytometry (MFC) before allogeneic hematopoietic cell transplantation (HCT) identifies patients at high risk of acute myeloid leukemia (AML) relapse, often occurring early after...
5.
Appelbaum J, Appelbaum F, Percival M
Blood Adv
. 2024 Aug;
8(15):4221-4222.
PMID: 39136970
No abstract available.
6.
Dohner H, DiNardo C, Appelbaum F, Craddock C, Dombret H, Ebert B, et al.
Blood
. 2024 Aug;
144(21):2169-2173.
PMID: 39133932
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an...
7.
8.
Rodriguez-Arboli E, Othus M, Orvain C, Ali N, Milano F, Davis C, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):905.e1-905.e14.
PMID: 38914227
Second allogeneic hematopoietic cell transplantation (HCT2) is potentially curative for adults with acute myeloid leukemia (AML) or myelodysplastic neoplasm (MDS)/AML experiencing relapse after a first allograft (HCT1), but prognostic factors...
9.
Olivieri D, Othus M, Orvain C, Rodriguez-Arboli E, Milano F, Sandmaier B, et al.
Leukemia
. 2024 Feb;
38(4):865-876.
PMID: 38388647
Racial and socioeconomic disparities impact outcomes after chemotherapy and limit access to allogeneic hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML), yet studies have yielded mixed results on the...
10.
Orvain C, Ali N, Othus M, Rodriguez-Arboli E, Milano F, Le C, et al.
Am J Hematol
. 2024 Feb;
99(5):862-870.
PMID: 38380817
Multiparameter flow cytometry (MFC) measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) independently predicts poor outcomes in acute myeloid leukemia (AML). Conversely, its prognostic value in the newly...